reorganize sections, frame image, remove Conko image
←Older revision
Revision as of 20:54, 13 September 2012
Line 2:
Line 2:
'''Henry I. Miller''' is senior research fellow at the [[Hoover Institution]], a conservative [[think tank]]. Prior to joining the Hoover Institution, Miller worked for 15 years at the [[U.S. Food and Drug Administration]] where he was an outspoken advocate of agricultural [[biotechnology]], including [[genetically modified organisms]] (GMOs). Miller was the founding director of the [[FDA Office of Biotechnology]] (from 1989-1994).
'''Henry I. Miller''' is senior research fellow at the [[Hoover Institution]], a conservative [[think tank]]. Prior to joining the Hoover Institution, Miller worked for 15 years at the [[U.S. Food and Drug Administration]] where he was an outspoken advocate of agricultural [[biotechnology]], including [[genetically modified organisms]] (GMOs). Miller was the founding director of the [[FDA Office of Biotechnology]] (from 1989-1994).
−
==
Background
==
+
==
Miller on Biotechnology
==
−
[[Image:Henry I. Miller.jpg|
left]]According to a a biographical profile in a 2003 report he co-authored, Miller's research "focuses on the relationship between science and regulation, the often-excessive costs of government regulation, models for regulatory reform, and federal and international oversight of genetically engineered products
.
As a consultant, he advises defendants' and plaintiffs' counsel and companies on a wide spectrum of regulatory strategies and problems."
Bonner Cohen, John Carlisle, Michael Fumento, Michael Gough, Henry
Miller
, Steven Milloy, Kenneth Smith and Elizabeth Whelan
(
eds), [http
:
//s28003.gridserver.com/wp-content/uploads/2007/12/fear_profiteers.pdf ''Fear Profiteers: Do ‘Socially Responsible’ Businesses Sow Health Scares to Reap Monetary Rewards?'', ], [[National
+
[[Image:Henry I. Miller.jpg|
frame|Henry I
. Miller (
Source
:
Hoover Institution
)|
left
]]With [[Gregory Conko]] he wrote in an article for the [[European Science and Environment Forum]] website which suggests that concerns about the safety of GM food are only because of "trade protectionism" and "anti-science fearmongering". In his book, ''The Frankenfood myth: how protest and politics threaten the biotech revolution'' (co-authored with Conko), Miller explains criticism of biotech as follows:
−
Center for Public Policy[[ and [[Junkscience.com]], undated bu approx 2000, pages 82-83.
+
−
+
−
According to the profile Miller "is a prominent academic researcher, author and regulatory consultant. He graduated from the Massachusetts Institute of Technology with a Bachelor of Science degree in Life Sciences and attended the University of California, San Diego, receiving the M.S. and M.D. degrees. After completing training in internal medicine as a Clinical Fellow in Medicine at Harvard Medical School, Dr. Miller spent several years as a Research Associate at the National Institutes of Health, helping to refine and employing the recombinant DNA ("gene-splicing"
)
techniques that were then emerging".
+
−
+
−
"Dr. Miller joined the FDA in 1979 and served in a number of posts involved with the new biotechnology. He was the medical reviewer for the early recombinant DNA-derived drugs evaluated by the FDA and was instrumental in the rapid approvals of human insulin and [[human growth hormone]] (the marketing approval of the former in five months was an FDA record at the time)," his profile states.
+
−
+
−
"He served at both the Center for Drug Evaluation and Review (CDER) and the Center for Biologics Evaluation and Review (CBER). Dr. Miller later served as Special Assistant to the FDA Commissioner, with responsibility for biotechnology issues (1984-89); and from 1989-94, he was the founding director of the FDA's Office of Biotechnology. During his government service, Dr. Miller
+
−
wrote and lectured frequently on the regulatory requirements for biotechnology products, and participated frequently on various expert and policy panels as a representative of the FDA or the US government. As the FDA's contact person for the Securities and Exchange Commission, he reviewed the accuracy of claims made by companies in their prospectuses about the likelihood and timing of drug approvals," his profile states.
+
−
+
−
"Dr. Miller's primary contributions have been in four areas: as a federal official, crafting and implementing science-based regulation of the new biotechnology, and explaining these policies to regulated industry, the scientific community, and the public; as a member of international panels and experts' groups, moving consensus toward the scientific view of risk and its regulation; making science and technology and their regulation more widely understood, via articles in newspapers and magazines; and performing research on and analyses of various issues related to science and technology," his profile states.
+
−
+
−
== Miller on Biotechnology==
+
−
[[Image:Gregory Conko.jpg
|
right|125px
]]With [[Gregory Conko]] he wrote in an article for the [[European Science and Environment Forum]] website which suggests that concerns about the safety of GM food are only because of "trade protectionism" and "anti-science fearmongering". In his book, ''The Frankenfood myth: how protest and politics threaten the biotech revolution'' (co-authored with Conko), Miller explains criticism of biotech as follows:
+
:"Demands were made for governmental protection against unseen, unlikely, and often largely imaginary risks. The products of the new biotechnology often were regarded as though they were mysterious and alien substances transported here from another galaxy, instead of the result of precise and well-understood scientific processes."
[[Henry I. Miller]] and [[Gregory P. Conko]], ''The Frankenfood myth: how protest and politics threaten the biotech revolution'', Praeger, 2004.
:"Demands were made for governmental protection against unseen, unlikely, and often largely imaginary risks. The products of the new biotechnology often were regarded as though they were mysterious and alien substances transported here from another galaxy, instead of the result of precise and well-understood scientific processes."
[[Henry I. Miller]] and [[Gregory P. Conko]], ''The Frankenfood myth: how protest and politics threaten the biotech revolution'', Praeger, 2004.
Line 42:
Line 29:
An undated TASSC newsletter (called "The Catalyst") contains an article stating that TASSC member-scientist Dr. Henry Miller, ("a visiting scholar from the [[Hoover Institution]])," helped draft the 5 Guiding Principles of TASSC. Listed along with Miller as another TASSC member who helped draft the Guiding Principles is [[James E. Enstrom]], a scientist whose work was cited in [[The U.S. Government's racketeering case against Big Tobacco]] as having assisted the tobacco industry in perpetrating fraud and deception upon the American public.
An undated TASSC newsletter (called "The Catalyst") contains an article stating that TASSC member-scientist Dr. Henry Miller, ("a visiting scholar from the [[Hoover Institution]])," helped draft the 5 Guiding Principles of TASSC. Listed along with Miller as another TASSC member who helped draft the Guiding Principles is [[James E. Enstrom]], a scientist whose work was cited in [[The U.S. Government's racketeering case against Big Tobacco]] as having assisted the tobacco industry in perpetrating fraud and deception upon the American public.
+
+
==Background==
+
According to a a biographical profile in a 2003 report he co-authored, Miller's research "focuses on the relationship between science and regulation, the often-excessive costs of government regulation, models for regulatory reform, and federal and international oversight of genetically engineered products. As a consultant, he advises defendants' and plaintiffs' counsel and companies on a wide spectrum of regulatory strategies and problems."
Bonner Cohen, John Carlisle, Michael Fumento, Michael Gough, Henry Miller, Steven Milloy, Kenneth Smith and Elizabeth Whelan (eds), [http://s28003.gridserver.com/wp-content/uploads/2007/12/fear_profiteers.pdf ''Fear Profiteers: Do ‘Socially Responsible’ Businesses Sow Health Scares to Reap Monetary Rewards?'', ], [[National
+
Center for Public Policy[[ and [[Junkscience.com]], undated bu approx 2000, pages 82-83.
+
+
According to the profile Miller "is a prominent academic researcher, author and regulatory consultant. He graduated from the Massachusetts Institute of Technology with a Bachelor of Science degree in Life Sciences and attended the University of California, San Diego, receiving the M.S. and M.D. degrees. After completing training in internal medicine as a Clinical Fellow in Medicine at Harvard Medical School, Dr. Miller spent several years as a Research Associate at the National Institutes of Health, helping to refine and employing the recombinant DNA ("gene-splicing") techniques that were then emerging".
+
+
"Dr. Miller joined the FDA in 1979 and served in a number of posts involved with the new biotechnology. He was the medical reviewer for the early recombinant DNA-derived drugs evaluated by the FDA and was instrumental in the rapid approvals of human insulin and [[human growth hormone]] (the marketing approval of the former in five months was an FDA record at the time)," his profile states.
+
+
"He served at both the Center for Drug Evaluation and Review (CDER) and the Center for Biologics Evaluation and Review (CBER). Dr. Miller later served as Special Assistant to the FDA Commissioner, with responsibility for biotechnology issues (1984-89); and from 1989-94, he was the founding director of the FDA's Office of Biotechnology. During his government service, Dr. Miller
+
wrote and lectured frequently on the regulatory requirements for biotechnology products, and participated frequently on various expert and policy panels as a representative of the FDA or the US government. As the FDA's contact person for the Securities and Exchange Commission, he reviewed the accuracy of claims made by companies in their prospectuses about the likelihood and timing of drug approvals," his profile states.
+
+
"Dr. Miller's primary contributions have been in four areas: as a federal official, crafting and implementing science-based regulation of the new biotechnology, and explaining these policies to regulated industry, the scientific community, and the public; as a member of international panels and experts' groups, moving consensus toward the scientific view of risk and its regulation; making science and technology and their regulation more widely understood, via articles in newspapers and magazines; and performing research on and analyses of various issues related to science and technology," his profile states.
==Affiliations==
==Affiliations==